RT Journal Article
T1 Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems.
A1 Miravitlles, Marc
A1 Huerta, Alicia
A1 Fernández-Villar, José Alberto
A1 Alcázar, Bernardino
A1 Villa, Guillermo
A1 Forné, Carles
A1 Cuesta, Maribel
A1 Crespo, Carlos
A1 García-Río, Francisco
K1 Chronic obstructive pulmonary disease
K1 Health utility
K1 Health related quality of life
K1 GOLD
K1 GesEPOC
K1 Enfermedad pulmonar obstructiva crónica
K1 Calidad de vida
K1 Salud
K1 Asma
K1 Ansiedad
AB BACKGROUNDTo determine generic utilities for Spanish chronic obstructive pulmonary disease (COPD) patients stratified by different classifications: GOLD 2007, GOLD 2013, GesEPOC 2012 and BODEx index.METHODSMulticentre, observational, cross-sectional study. Patients were aged ≥40 years, with spirometrically confirmed COPD. Utility values were derived from EQ-5D-3 L. Means, standard deviations (SD), medians and interquartile ranges (IQR) were computed based on the different classifications. Differences in median utilities between groups were assessed by non-parametric tests.RESULTS346 patients were included, of which 85.5% were male with a mean age of 67.9 (SD = 9.7) years and a mean duration of COPD of 7.6 (SD = 5.8) years; 80.3% were ex-smokers and the mean smoking history was 54.2 (SD = 33.2) pack-years. Median utilities (IQR) by GOLD 2007 were 0.87 (0.22) for moderate; 0.80 (0.26) for severe and 0.67 (0.42) for very-severe patients (p < 0.001 for all comparisons). Median utilities by GOLD 2013 were group A: 1.0 (0.09); group B: 0.87 (0.13); group C: 1.0 (0.16); group D: 0.74 (0.29); comparisons were statistically significant (p < 0.001) except A vs C. Median utilities by GesEPOC phenotypes were 0.84 (0.33) for non exacerbator; 0.80 (0.26) for COPD-asthma overlap; 0.71 (0.62) for exacerbator with emphysema; 0.72 (0.57) for exacerbator with chronic bronchitis (p < 0.001). Comparisons between patients with or without exacerbations and between patients with COPD-asthma overlap and exacerbator with chronic bronchitis were statistically-significant (p < 0.001). Median utilities by BODEx index were: group 0-2: 0.89 (0.20); group 3-4: 0.80 (0.27); group 5-6: 0.67 (0.29); group 7-9: 0.41 (0.31). All comparisons were significant (p < 0.001) except between groups 3-4 and 5-6.CONCLUSIONIrrespective of the classification used utilities were associated to disease severity. Some clinical phenotypes were associated with worse utilities, probably related to a higher frequency of exacerbations. GOLD 2007 guidelines and BODEx index better discriminated patients with a worse health status than GOLD 2013 guidelines, while GOLD 2013 guidelines were better able to identify a smaller group of patients with the best health.
PB BioMed Central
YR 2014
FD 2014
LK http://hdl.handle.net/10668/2283
UL http://hdl.handle.net/10668/2283
LA en
NO Miravitlles M, Huerta A, Fernández-Villar JA, Alcázar B, Villa G, Forné C, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes. 2014; 12:120
NO Journal Article; Observational Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 6, 2025